Companies: 10,795·Total market cap: $144.5T
Rein Therapeutics Inc.

Rein Therapeutics Inc.

RNTXNASDAQHealthcare● Active
$0.95
+$0.01(+0.59%)
Market Cap$26521833
P/E Ratio
52W High$2.18
52W Low$0.915
Overview

Rein Therapeutics Inc. (RNTX) Stock Overview

Key statistics and deep links to earnings, valuation, revenue, dividends, and more.

FMP · RNTX · as of Jun 9, 2026

Key Statistics

EPS (TTM)$-1.90rntx eps ttm · rntx earnings per shareEarnings history
PE Ratio (TTM)rntx pe ratio ttm · rntx price to earningsPE Ratio deep dive
Revenue (TTM)0.00rntx revenue ttm · rntx annual revenueFull revenue history
Dividend YieldNo Dividenddoes rntx pay dividends · rntx dividend yieldDividend history
Shares Outstanding25.4Mrntx shares outstanding · rntx floatShares outstanding history
Next EarningsAug 13, 2026Est.rntx earnings date · rntx next earningsEarnings history

Financial Snapshot

Full Financials
FY 2025Revenue$0.00
202320242025
rein therapeutics inc. revenue · rntx revenue 2025
FY 2025Net Income-$49.9M▲ +20.69% YoY
202320242025
rein therapeutics inc. net income · rntx profit 2025
FY 2025EPS$-1.96▲ +44.16% YoY
202320242025
rntx eps · rein therapeutics inc. earnings per share 2025
TTM:Revenue: $0.00Net Income: -$50.2MEPS: $-1.90View income statement →

Analyst Ratings & Price Target

Full Forecast
SellBuy
Buy2 analystsis rntx a buy · rntx analyst rating
Strong Buy
0
Buy
1
Hold
1
Sell
0
Strong Sell
0
12-Month Price Target
$6.00Low
$0.95Current
$6.00Avg Target532.44% upside
$6.00High
rntx price target · rntx 12 month forecast

Total: 2 · Buy rate: 50.0%

The RNTX analyst consensus is Buy, based on ratings from 2 Wall Street analysts over the past 3 months. The average 12-month price target is $6.00, representing +532.44% upside from the current price of $0.95.

Stock Performance

Full History
1D+0.59%
1W-6.07%
1M-22.24%
3M-20.94%
YTD-18.22%
1Y-52.09%
5Y-55.25%

About Rein Therapeutics Inc.

CEOJames Brian Windsor
IPO DateJun 29, 2017
Employees11
CountryUS
Websitereintx.com

Rein Therapeutics Inc. operates as a clinical-stage biopharmaceutical enterprise focused on discovering and bringing to market novel therapeutic solutions for various conditions, notably cancer. The c…

what is rein therapeutics inc. · rntx stock overview · rein therapeutics inc. company profile · who is rein therapeutics inc. ceo · rntx NASDAQ · rein therapeutics inc. headquarters · rein therapeutics inc. business segments

About Stock Overview & Key Data

Rein Therapeutics Inc. (RNTX) is a Healthcare company in the Medical - Pharmaceuticals industry, listed on NASDAQ since Jun 29, 2017. As of the latest trading session, RNTX stock price is $0.95, with a market capitalization of $26.5M. The stock has returned -52.09% over the past 12 months and -18.22% year-to-date.

According to 2 Wall Street analysts, the consensus rating for Rein Therapeutics Inc. stock is Buy, with an average 12-month price target of $6.00. In fiscal year 2025, Rein Therapeutics Inc. reported revenue of — and net income of -$49.9M. For detailed data — including Rein Therapeutics Inc. revenue history, earnings, dividends, and PE ratio — use the tabs above.

Frequently Asked Questions

As of the latest trading session, Rein Therapeutics Inc. (RNTX) stock price is $0.95. The stock is traded on NASDAQ under the ticker symbol RNTX. The 52-week range is $0.92 – $2.18.

RNTX stock priceRNTX quote todaylive ticker
Data provided by Financial Modeling PrepLast updated: Jun 9, 2026Not investment advice